中文名称:PAK抑制剂(KPT-9274) 英文名称:KPT-9274 保存条件: 低温运输,-20℃避光保存,有效期半年。 纯度规格: 99.9% 产品类别: 细胞生物学试剂 PAK抑制剂(KPT-9274) 中文名称:PAK抑制剂(KPT-9274) 英文名称:KPT-9274 产品规格:1mL(10mM)|5mg|10mg|50mg|100mg KPT-9274是PAK的抑制剂,在MTT试验中测定的IC...
产品名称:KPT-9274 产品别名:见爱必信官网 英文别名:KPT-9274 靶点:PAK CAS:1643913-93-2 纯度:>98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: KPT-9274 is an orally bioavailable small...
KPT-9274CAS号: 1643913-93-2分子式: C35H29F3N4O3分子量: 610.63描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)产品描述 描述 KPT-9274 is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 ...
英文名称:KPT-9274 分子式:C35H29F3N4O3 纯度:99.28% 产地:北京 包装规格:1mL(10mM)|5mg|10mg|50mg|100mg 品牌:百奥莱博 货号:M00598 CAS编号: 1643913-93-2 特别提示:包括PAK抑制剂(KPT-9274)在内,本公司的所有产品仅可用于科研实验,严禁用于临床医疗及其他非科研用途!产品名称:PAK抑制剂(KPT-9274)...
KPT-9274性质、用途与生产工艺 生物活性 KPT 9274 ( ATG-019) 是一种具有口服活性的小分子化合物,是非竞争性的PAK4和NAMPT双重抑制剂。在cell-free的酶活实验中,对NAMPT的IC50值约为120 nM。 靶点 TargetValue PAK4 (Cell-free assay) NAMPT (Cell-free assay)~120 nM ...
PAK抑制剂(KPT-9274) 英文名称: KPT-9274 总访问: 335 国产/进口: 国产 半年访问: 18 产地/品牌: 百奥莱博 产品类别: 细胞生物学试剂 规格: 1643913-93-2 最后更新: 2024-11-4 货号: M00598 CAS 号: 1643913-93-2 参考报价: 立即询价 电话咨询 ...
KPT-9274详情 评价(0) 货号:ajci13472 CAS:1643913-93-2 别名: 分子式:C35H29F3N4O3 分子量:610.62 纯度:>98% 溶解度:≥ 22.45mg/mL in DMSO 储存:Store at -20°C 库存:现货 Background KPT-9274 is a selective and orally bioavailable allosteric inhibitor of PAK4 [1][2][3]. ...
KPT-9274 is a first-in-class orally bioavailable small molecule targeting two proteins that could play an important role in cancer development: PAK4 and NAMPT. PAK4 PAK4 is member of the PAK family of kinases that includes 6 proteins, PAK1-6. PAK4 is a signaling protein regulating numerous...
KPT-9274 is a first-in-class dual inhibitor of NAMPT and p21-activated kinase 4 (PAK-4). PAK-4 is a serine threonine kinase which is a downstream effector of RAS and believed to modulate β-catenin activity. KPT-9274 is currently in clinical assessment in a first-in-human phase I ...
Furthermore, in a PDX mouse model of AML, KPT-9274 treatment significantly reduced disease burden (p<0.001) and prevented leukemic infiltration in spleen, bone marrow, and liver. In addition, KPT-9274 treatment induced differentiation, which is evident by a decrease in blast percentage and an ...